A VISIONaerie® approach
We discover, develop, and commercialize first-in-class therapies for the treatment of patients with glaucoma, dry eye, retinal diseases and other diseases of the eye
News Highlights
Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug ... Aerie Pharmaceuticals Announces Successful Interim 90-Day Topline Data From... Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval ...STOCK Quote
NASDAQ: AERI
$9.15USD
Oct 21, 4:00 PM ET
VOLUME
0
DAY LOW/HIGH
$9.01/$9.58
52 - WEEK LOW/HIGH
$9.03/$26.26
